Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
NCT04846010 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2000
Last updated 2021-05-26
Summary
Post-acute sequelae of SARS-CoV-2 infection can cause multiple system function disorders, and complicated symptoms last for an extended period. The virus can cause this continued infection, or the virus causes immune system function disorder and post-infectious autoimmune disease. The clinical symptoms can be smell loss, taste loss to liver function disorder, kidney function failure, different. No matter how complicated the systems showed in the clinic, all of the symptoms are due to the specific cells being damaged. Our clinical study is focused on recovering the damaged structure and function of the cells that could restore the organ function back to normal or close to normal
Conditions
- Sequelae of; Infection
- Post Infection Glomerulonephritis
- Post-Infectious Peripheral Neuralgia
- Post-Infectious Disorder (Disorder)
- Post-Infectious Arthritis
- Post-Infectious Polyneuritis
- Post-Infectious Parkinsonism
- Post-Infectious Hypothyroidism
- Post Infectious Osteoarthritis
- Anxiety Disorders
- Depression
- Depression, Anxiety
- Depression, Bipolar
- Insomnia
- GERD
- Gastro Esophageal Reflux
- Hepatitis
- Glomerulonephritis
Interventions
- COMBINATION_PRODUCT
-
PurWet
(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
- COMBINATION_PRODUCT
-
FurFat
(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
- COMBINATION_PRODUCT
-
PurApo
(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
- COMBINATION_PRODUCT
-
PurPhl
(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
- COMBINATION_PRODUCT
-
PurClo
(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
- COMBINATION_PRODUCT
-
PurInf
(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
- COMBINATION_PRODUCT
-
Smoliv
(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
Sponsors & Collaborators
-
All Natural Medicine Clinic, LLC
lead OTHER
Principal Investigators
-
Wanzhu Hou, CMD · All Natural Medicine Clinic, LLC
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2022-05-01
- Completion
- 2022-10-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
NCT01573572 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells
NCT05187104 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT07093385 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
NCT00056823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT01577381 ·Status: TERMINATED ·Phase: PHASE2
-
Supplemental Adjuvants for Intracellular Nutrition and Treatment
NCT00893724 ·Status: UNKNOWN ·Phase: NA
-
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
NCT05894564 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
NCT00078221 ·Status: UNKNOWN ·Phase: PHASE3
-
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
NCT00087763 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
NCT01846351 ·Status: COMPLETED
-
Evaluation and Treatment of Patients With Retinal Disease
NCT00005784 ·Status: COMPLETED
-
Fluocinolone Implant to Treat Macular Degeneration
NCT00008515 ·Status: COMPLETED ·Phase: PHASE1
-
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
NCT00637377 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
NCT00509795 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
NCT04270669 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
NCT00299507 ·Status: COMPLETED ·Phase: PHASE3
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT04339764 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
NCT00088192 ·Status: COMPLETED ·Phase: NA
-
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
NCT04120636 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AAVCAGsCD59 for the Treatment of Wet AMD
NCT03585556 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
NCT00211458 ·Status: COMPLETED ·Phase: PHASE2